Of the reduction, 29 percent was due to treatment of metastatic breast cancer, 25 percent due to mammography screening<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Jan. 16, 2024 (HealthDay News) — In the United States, breast cancer screening and treatment were associated with a 58 percent reduction in breast cancer mortality in 2019 compared with 1975, according to a study published in the Jan. 16 issue of the Journal of the American Medical Association<\/em>.<\/p>\n Jennifer L. Caswell-Jin, M.D., from the Stanford University School of Medicine in California, and colleagues simulated the relative association of breast cancer screening, treatment of stage I to III breast cancer, and treatment of metastatic breast cancer with improved mortality using aggregated observational and clinical trial data on the dissemination and effects of screening and treatment.<\/p>\n The researchers found that the age-adjusted breast cancer mortality rate in the United States was 48\/100,000 women in 1975 and 27\/100,000 women in 2019. The combination of screening, stage I to III treatment, and metastatic treatment was associated with a 58 percent reduction in breast cancer mortality in 2019; 29, 47, and 25 percent of the reduction was associated with treatment of metastatic breast cancer, treatment of stage I to III breast cancer, and mammography screening, respectively. The greatest change in survival after metastatic recurrence occurred between 2000 and 2019 based on simulations, from 1.9 to 3.2 years.<\/p>\n “The results suggest that advances in the treatment of metastatic breast cancer were associated with lower rates of breast cancer mortality in the United States,” the authors write.<\/p>\n Several authors disclosed ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n